CoChat

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Open access
Ardini, Elena, Bosotti, Roberta, Borgia, Andrea Lombardi, De Ponti, Cristina, Somaschini, Alessio, Cammarota, Rosaria, Amboldi, Nadia, Raddrizzani, Laura, Milani, Andrea, Magnaghi, Paola, Ballinari, Dario, Casero, Daniele, Gasparri, Fabio, Banfi, Patrizia, Avanzi, Nilla, Saccardo, Maria B., Alzani, Rachele, Bandiera, Tiziano, Felder, Eduard, Donati, Daniele, Pesenti, Enrico, Sartore-Bianchi, Andrea, Gambacorta, Marcello, Pierotti, Marco A., Siena, Salvatore, Veronese, Silvio, Galvani, Arturo, Isacchi, Antonella · 2014 · Molecular Oncology
Cited by 157

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The NTRK1 gene encodes Tropomyosin‐related kinase A (TRKA), the high‐affinity Nerve Growth Factor Receptor. NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3‐NTRK1) resulting in expression of the oncogenic chimeric protein TPM3‐TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC. The KM12 human CRC cell line expresses the chimeric TPM3‐TRKA protein and is hypersensitive to TRKA kinase inhibition. We report the detailed characterization of the TPM3‐NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS‐P626, a novel highly potent and selective TRKA inhibitor. NMS‐P626 suppressed TPM3‐TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors. Finally, using quantitative reverse transcriptase PCR and immunohistochemistry (IHC) we identified the TPM3‐NTRK1 rearrangement in a CRC clinical sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.06.001

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 157

Metadata

Authors
Ardini, E., Bosotti, R., Borgia, A. L., De Ponti, C., Somaschini, A., Cammarota, R., Amboldi, N., Raddrizzani, L., Milani, A., Magnaghi, P., Ballinari, D., Casero, D., Gasparri, F., Banfi, P., Avanzi, N., Saccardo, M. B., Alzani, R., Bandiera, T., Felder, E., Donati, D., Pesenti, E., Sartore-Bianchi, A., Gambacorta, M., Pierotti, M. A., Siena, S., Veronese, S., Galvani, A., & Isacchi, A.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-06-12
Volume
8
Issue
8
Pages
1495-1507
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2008264953
Cited by
157
References
10
FWCI
5.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. https://app.cochat.ai/papers/10.1016/j.molonc.2014.06.001
The paper
Ardini, E., Bosotti, R., Borgia, A. L., De Ponti, C., Somaschini, A., Cammarota, R., Amboldi, N., Raddrizzani, L., Milani, A., Magnaghi, P., Ballinari, D., Casero, D., Gasparri, F., Banfi, P., Avanzi, N., Saccardo, M. B., Alzani, R., Bandiera, T., Felder, E., . . . Isacchi, A. (2014). The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Molecular Oncology. https://doi.org/10.1016/j.molonc.2014.06.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.